

*25.06.2021*

<b>11:30 - 12:30</b>	<b>Type: Industry satellite</b> <b>Title: Industry satellite symposium - GSK</b>	<b>Channel 1</b>
----------------------	---	------------------

11:30 - 12:30     **TBC**

<b>12:45 - 13:20</b>	<b>Type: Opening and closure session</b> <b>Title: Welcome to ESMO Gynae 2021 and Keynote address</b> Moderation: Susana Banerjee, GB; Domenica Lorusso, IT; Andres Maria Poveda Velasco, ES	<b>Channel 1</b>
----------------------	--	------------------

12:45 - 12:50     **Live welcome**  
A.M. Poveda Velasco, Valencia/ES

12:50 - 12:55     **Introduction to the Keynote lecture**  
S. Banerjee, London/GB

12:55 - 13:20     **Keynote lecture: DNA damage repair in ovarian cancer and PARP inhibitors resistance**  
A. Oza, Toronto/CA

<b>13:35 - 14:50</b>	<b>Type: Educational session</b> <b>Title: Treatment of newly diagnosed ovarian cancer: Where are we in 2021 and what's next?</b> Moderation: Nicole Concin, AT; David SP Tan, SG	<b>Channel 1</b>
13:35 - 13:50	<b>The evolving role of molecular profiling for therapeutic stratification in newly diagnosed ovarian cancer</b> <u>D.S. Tan</u> , Singapore/SG	
13:50 - 14:05	<b>The role of surgery for newly diagnosed ovarian cancer: Current status and future directions</b> <u>S. Mahner</u> , Munich/DE	
14:05 - 14:20	<b>First line maintenance therapy for ovarian cancer in 2021: What are the options?</b> <u>I. Ray-Coquard</u> , Lyon/FR	
14:20 - 14:35	<b>Horizon scanning: What's next for systemic therapy in ovarian cancer - first line and beyond?</b> <u>D. Lorusso</u> , Rome/IT	
14:35 - 14:50	<b>Live Q&amp;A and discussion</b>	
<b>15:05 - 16:20</b>	<b>Type: Clinical case session</b> <b>Title: 1st line maintenance strategy options for advanced ovarian cancer by HRD profile</b> Moderation: David Cibula, CZ; Amit Oza, CA	<b>Channel 1</b>
15:05 - 15:25	<b>Clinical case - What options for HRD patients? Criteria for treatment choice</b> <u>E. Kohn</u> , Bethesda/US	
15:25 - 15:45	<b>Clinical case - What options for HR proficient patients? Criteria for treatment choice</b> <u>N. Colombo</u> , Milan/IT	
15:45 - 16:05	<b>Clinical case - Combination vs sequence: Clinical implications</b> <u>S. Lheureux</u> , Toronto/CA	
16:05 - 16:20	<b>Live Q&amp;A and discussion</b>	

<b>16:35 - 17:35</b>	<b>Type: Industry satellite</b> <b>Title: Industry satellite symposium - AstraZeneca</b>	<b>Channel 1</b>
16:35 - 17:35	<b>TBC</b>	
<b>17:50 - 19:05</b>	<b>Type: YO session</b> <b>Title: How to deal with the different challenges in your professional career</b> Moderation: Maria Kfoury, FR; Elene Mariamidze, GE; Alexandra Tyulyandina, RU	<b>Channel 1</b>
17:50 - 18:00	<b>How to deal with social media self-representation and networking</b> <u>D. Dizon</u> , Providence/US	
18:00 - 18:10	<b>How to start an international collaboration - Developing and integrating research in clinical practice</b> <u>M. Mirza</u> , Copenhagen/DK	
18:10 - 18:20	<b>How to seize opportunities and progress your career in the gynae-oncology field</b> <u>C. Sessa</u> , Bellinzona/CH	
18:20 - 19:05	<b>Live Q&amp;A and discussion</b>	

26.06.2021

<b>11:30 - 12:30</b>	<b>Type: Industry satellite</b> <b>Title: Industry satellite symposium 3 (TBC)</b>	<b>Channel 1</b>
----------------------	---	------------------

11:30 - 12:30     **TBC**

<b>12:45 - 14:15</b>	<b>Type: Abstract session</b> <b>Title: Best of abstracts session</b> Moderation: Elise Kohn, US; Domenica Lorusso, IT	<b>Channel 1</b>
----------------------	--	------------------

12:45 - 12:55     **Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation**  
A.M. Poveda Velasco, Valencia/ES

12:55 - 13:05     **Long term safety and secondary efficacy end points in the ENGOT-OV16/NOVA phase 3 trial on Niraparib in recurrent ovarian cancer**  
M. Mirza, Copenhagen/DK

13:05 - 13:15     **Discussion**  
E. Kohn, Bethesda/US

13:15 - 13:30     **Live Q&A and discussion**

13:30 - 13:40     **Rucaparib vs chemotherapy in patients with advanced, relapsed ovarian cancer and a deleterious BRCA mutation: Efficacy and safety from ARIEL4, a randomized phase 3 study**  
R. Kristeleit, London/GB

13:40 - 13:50     **Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy +/- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC)**  
K. Moore, Oklahoma City/US

13:50 - 14:00     **Discussion**  
S. Banerjee, London/GB

14:00 - 14:15     **Live Q&A and discussion**

<b>14:30 - 15:45</b>	<b>Type: Educational session</b> <b>Title: Treatment and biomarkers of recurrent ovarian cancer: Where are we in 2021 and what's next?</b> Moderation: Andres Maria Poveda Velasco, ES; Ignacio Romero, ES	<b>Channel 1</b>
14:30 - 14:50	<b>Surgery in recurrent ovarian cancer: Patient selection and impact on 2nd line therapeutic strategies</b> <u>P. Harter</u> , Essen/DE	
14:50 - 15:10	<b>Do all patients with recurrent ovarian cancer need systemic therapy and which is the optimal treatment algorithm?</b> <u>M. Friedlander</u> , Randwick/AU	
15:10 - 15:30	<b>Current and emerging biomarkers in recurrent OvCa</b> <u>S. Banerjee</u> , London/GB	
15:30 - 15:45	<b>Live Q&amp;A and discussion</b>	
<b>16:00 - 17:00</b>	<b>Type: Controversy session</b> <b>Title: Immunotherapy in ovarian cancer: Is there a future in clinical practice?</b> Moderation: Robert Coleman, US; Mansoor Mirza, DK	<b>Channel 1</b>
16:00 - 16:15	<b>Live introduction and first vote</b> <u>S. Not Yet Confirmed</u> , /CH	
16:15 - 16:30	<b>Yes</b> <u>E. Pujade-Lauraine</u> , Paris/FR	
16:30 - 16:45	<b>No</b> <u>K. Moore</u> , Oklahoma City/US	
16:45 - 17:00	<b>Second vote and live conclusions</b> <u>S. Not Yet Confirmed</u> , /CH	
<b>17:15 - 17:20</b>	<b>Type: Opening and closure session</b> <b>Title: Live closing remarks</b> Moderation: Susana Banerjee, GB; Domenica Lorusso, IT; Andres Maria Poveda Velasco, ES	<b>Channel 1</b>
17:15 - 17:20	<b>Live closing remarks</b> <u>S. Not Yet Confirmed</u> , /CH	